

LABORATORY

ANTIRETROVIRAL THERAPEUTIC DRUG MONITORING

Gary Maartens, MB ChB, FCP (SA), MMed, DTM&H Division of Clinical Pharmacology, University of Cape Town

Antiretroviral therapeutic drug monitoring (TDM) is an additional monitoring tool to assist in the management of HIV-infected patients. Antiretroviral TDM is frequently undertaken in Europe, but less often in the USA. This overview will assess the principles, current evidence for, and limitations of TDM. Lastly, the potential role of TDM in southern Africa will be discussed.

GENERAL PRINCIPLES OF TDM

The vast majority of drugs used in clinical practice do not require TDM. It is far easier for clinicians to adopt a 'one size fits all' approach to dosing. Alternatively doses may be modified according to response. However, with some drugs this will result in high rates of toxicity, or suboptimal efficacy.

The characteristics that make drugs suitable for TDM include:

- A narrow therapeutic window
- Good correlation between drug concentration and effect or toxicity
- Variable pharmacokinetics in different individuals
- The availability of a reliable assay.

Digoxin and the first-line anticonvulsants are examples of drugs where TDM plays an important role. However, even when all of these characteristics are present, TDM is seldom done as a routine part of management for every patient. Clinicians typically use TDM if there are clinical concerns such as toxicity, poor efficacy, drug interactions, or special groups at risk of altered levels. This use of TDM is rational and appropriate, as there are very few randomised controlled trials to support the routine use of TDM.

WHICH ANTIRETROVIRALS ARE SUITABLE FOR TDM?

The nucleoside reverse transcriptase inhibitors (NRTIs) are prodrugs, which require activation by intracellular phosphorylation. There is a poor correlation between plasma NRTI levels and effect. Only a few laboratories are capable of measuring intracellular levels. NRTIs are therefore not suitable for TDM.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) display highly variable pharmacokinetics. The key cytochrome P450 isoenzyme responsible for metabolising efavirenz, CYP2B6, has a polymorphism that results in slower metabolism. This polymorphism occurs much more frequently in African Americans than Caucasians¹ – it is unclear whether

this polymorphism will occur commonly in southern Africa. There is a correlation between higher plasma levels and neuropsychiatric adverse effects of efavirenz, and between lower levels and virological failure.² A population pharmacokinetic study has shown that Thai and South African patients have lower clearance of nevirapine, resulting in greater exposure, than patients in 'Western countries.³ This may account in part for high rates of nevirapine-induced hepatotoxicity, particularly among women with a lower body mass index, reported in a South African study.⁴ Higher nevirapine levels are associated with a greater chance of virological success.⁵

The protease inhibitors (PIs) also have highly variable pharmacokinetics. Plasma concentrations of PIs have been shown to correlate with virological success.⁶ High levels of certain PIs correlate with adverse drug reactions, notably nephrolithiasis with indinavir⁷ and dyslipidaemia with lopinavir/ritonavir.⁸

Therefore both NNRTIs and PIs have many characteristics that make them potentially suitable candidates for TDM.

ARE RELIABLE ANTIRETROVIRAL ASSAYS AVAILABLE?

Currently there are no commercial kits to measure drug levels of antiretrovirals, though a few are in development, so antiretroviral TDM is conducted by laboratories that have developed their own in-house assays. It is therefore essential that laboratories participate in regular quality control to ensure that their assays are reliable. In a recent survey of laboratories conducting TDM, only 12 out of 31 had assays that were in the acceptable range for more than 90% of measurements.⁹

LIMITATIONS OF TDM

A number of randomised controlled trials have been conducted to assess the value of routine TDM. In these studies patients

were randomised to control or TDM arms, where the treating clinician was advised about the antiretroviral level and, if necessary, to adjust the dose. Two of these studies^{10,11} showed higher rates of virological suppression in the TDM arms. However, a number of other studies have failed to show a benefit for routine TDM.^{12,13} One problem encountered in these randomised trials is that clinicians often did not make the recommended dose adjustments. In some trials the follow-up was very short. Lastly, the trials were under-powered. Until a large trial is conducted to address the weaknesses of the existing studies, there does not appear to be a role for routine TDM for all patients treated with antiretrovirals.

A recent study¹⁴ found that drug levels, particularly for Pls, were very variable in individual patients sampled at different times. This could partly be explained by the variability in the effect of dosing with food, which is important for the Pls studied. In addition, adherence can clearly affect drug levels; indeed, TDM is one tool to detect poor adherence. Controlling for adherence is difficult in clinical practice. This study¹⁴ highlights the importance of not making major clinical decisions on the basis of a single TDM result.

PATIENTS AT HIGHER RISK OF DRUG LEVELS OUTSIDE REFERENCE RANGES

Given that current evidence does not support routine TDM, it makes sense to utilise TDM in patients at particular risk for either suboptimal or toxic levels.

CHILDREN

Several important physiological changes in childhood, particularly early childhood, affect the pharmacokinetics of drugs.¹⁵ Firstly, the volume of distribution is affected as total body water is high in neonates and remains high in young children. Neonates have impaired drug absorption, metabolism and excretion, while in young children these parameters are enhanced compared with adults. Many authorities therefore recommend TDM in young children, especially as there are very limited data available for most antiretrovirals in children.

PREGNANCY

Many physiological changes in pregnancy affect pharmacokinetics:¹⁶

- Increased GIT motility
- Decreased protein binding
- Increased volume of distribution (fat and water)
- Mild hepatic enzyme induction
- Increased renal excretion.

Up to a third of pregnant epileptics experience an increased frequency of seizures owing to sub-therapeutic anticonvulsant levels, illustrating that these physiological changes of pregnancy are clinically relevant. A recent study showed lower lopinavir levels in pregnant women.¹⁷ Despite this, the women still had good virological suppression. This change in PI levels induced by pregnancy is likely to be relevant when a degree of

PI resistance is present – TDM should be considered in this setting.

DRUG INTERACTIONS

Many Pls are substrates of the important drug transporter, P glycoprotein. Their levels can be affected by drugs that inhibit or induce P glycoprotein. Pls and NNRTIs are metabolised by the cytochrome P450 system, and their levels can be affected by drugs that inhibit or induce this system. If a drug known to have such interactions has to be coadministered, TDM should be considered.

LIVER DISEASE

PIs and NNRTIs are metabolised by the cytochrome P450 system, which occurs primarily in the liver. Unlike renal disease, there is no accurate biochemical marker to indicate how much hepatic impairment is present. TDM should therefore be considered for patients with evidence of liver failure, as they may experience toxicity due to high levels.

INTEGRATING TDM AND PI RESISTANCE DATA – WHAT'S THE IQ?

PI resistance can to a certain extent be overcome by increasing the levels. It therefore makes sense to integrate the resistance data and the drug level. This is done using the inhibitory quotient (IQ), which is calculated by dividing the trough level by a factor, depending on the resistance test conducted. This is typically a genotypic test, and the trough level is divided by the number of major PI mutations. This genotypic IQ has been shown to correlate with virological success in PI-experienced patients.¹⁸

Note that this strategy cannot be used with the NNRTIs, as a single mutation generally confers very high-level resistance, which cannot be overcome by increasing the dose.


A ROLE FOR TDM IN SOUTHERN AFRICA?

Antiretroviral TDM could play an important adjunctive role in our area. Clearly this will be a limited resource, confined to high-risk patients or to those with some degree of PI resistance. There is a danger that laboratories will offer TDM without the necessary quality assurance. Until commercial kits become available, TDM should only be conducted by specialist pharmacology laboratories that participate in regular quality assurance.

REFERENCES

- Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-2400.
- Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. *AIDS* 2001; 15: 71-75.
- Kappelhoff BS, van Leth F, MacGregor TR, Lange JM, Beijnen JH, Huitema AD. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. *Antivir Ther* 2005; 10: 145-155.
- Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected patients. J Infect Dis 2005; 191: 825-829.
- Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1 infected individuals. AIDS 2001; 15: 1089-1095.





- Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000; 14: 1333-1339.
- Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13: 473-478.
- Gonzalez de Requena D, Blanco F, Garcia-Benayas T, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. *AIDS Patient Care STDS* 2003; 17: 443-445.
- Droste JA, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr 2003; 32: 287-291.
- Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003; 17: 1157-1165.
- Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002; 16: 551-560.
- Haas DW. Can responses to antiretroviral therapy be improved by therapeutic drug monitoring? *Clin Infect Dis* 2006; 42: 1197–1199.

- Khoo SH, Lloyd J, Dalton M, et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN) – a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr 2006; 41: 461-467.
- Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42: 1189-1196.
- Fraaij PL, Rakhmanina N, Burger DM, de Groot R. Therapeutic drug monitoring in children with HIV/AIDS. *Ther Drug Monit* 2004; 26: 122-136.
- Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. *Clin Pharmacokinet* 2004; 43: 1071–1087.
- Stek AM, Capparelli E, Best B, et al. Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026. XV International AIDS Conference, 11-16 July 2004, Bangkok, Thailand.
- Marcelin AG, Cohen-Codar I, King MS, et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother 2005; 49: 1720-1726.